{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:17:19Z","timestamp":1772025439640,"version":"3.50.1"},"update-to":[{"DOI":"10.1007\/s00705-017-3573-0","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"record-id":"39215"}],"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00705-017-3573-0","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T02:50:48Z","timestamp":1507171848000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["RETRACTED ARTICLE: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice"],"prefix":"10.1007","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-2218","authenticated-orcid":false,"given":"Sherief","family":"Abd-Elsalam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Sharaf-Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaimaa","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asem","family":"Elfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehab","family":"Badawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef K.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"issue":"2","key":"3573_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1871526517666170417143216","volume":"17","author":"OA Ahmed","year":"2017","unstructured":"Ahmed OA, Kaisar HH, Hawash N et al (2017) Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets 17(2):95\u2013100","journal-title":"Infect Disord Drug Targets"},{"key":"3573_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1128\/jcm.32.4.884-892.1994","volume":"32","author":"F McOmish","year":"1994","unstructured":"McOmish F, Yap PL, Dow BC et al (1994) Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 32:884\u2013892","journal-title":"J Clin Microbiol"},{"key":"3573_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","volume":"54","author":"MA Khattab","year":"2011","unstructured":"Khattab MA, Ferenci P, Hadziyannis SJ et al (2011) Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 54:1250\u20131262","journal-title":"J Hepatol"},{"key":"3573_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"SM Kamal","year":"2008","unstructured":"Kamal SM, Nasser IA (2008) Hepatitis C genotype 4: what we know and what we don\u2019t yet know. Hepatology 47:1371\u20131383","journal-title":"Hepatology"},{"key":"3573_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S et al (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:45\u201357","journal-title":"J Hepatol"},{"key":"3573_CR6","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1097\/MD.0000000000000204","volume":"93","author":"AE AbdElrazek","year":"2014","unstructured":"AbdElrazek AE, Bilasy SE, Elbanna AE et al (2014) Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore) 93:e204","journal-title":"Medicine (Baltimore)"},{"key":"3573_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.26744","volume":"59","author":"DB Smith","year":"2014","unstructured":"Smith DB, Bukh J, Kuiken C et al (2014) Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology 59:318\u2013327","journal-title":"Hepatology"},{"key":"3573_CR8","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1111\/j.1572-0241.2007.01538.x","volume":"102","author":"SM Kamal","year":"2007","unstructured":"Kamal SM (2007) Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterol 102:2582\u20132588","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 1","key":"3573_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/liv.12724","volume":"35","author":"W Abdel-Razek","year":"2015","unstructured":"Abdel-Razek W, Waked I (2015) Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 35(Suppl. 1):27\u201334","journal-title":"Liver Int"},{"issue":"4","key":"3573_CR10","first-page":"331","volume":"27","author":"E Cholongitas","year":"2014","unstructured":"Cholongitas E, Papatheodoridis GV (2014) Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol. 27(4):331\u2013337","journal-title":"Ann Gastroenterol."},{"key":"3573_CR11","unstructured":"AASLD\/IDSA\/IAS-USA (2014) Recommendations for testing, managing, and treating hepatitis C. http:\/\/hcvguidelines.org. Accessed 24 April 2014"},{"issue":"14 Suppl","key":"3573_CR12","first-page":"S340","volume":"18","author":"TT Tran","year":"2012","unstructured":"Tran TT (2012) A review of standard and newer treatment strategies in hepatitis C. Am J Manag Care 18(14 Suppl):S340\u2013S349","journal-title":"Am J Manag Care"},{"issue":"Suppl 1","key":"3573_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1478-3231.2011.02702.x","volume":"32","author":"M Bourli\u00e8re","year":"2012","unstructured":"Bourli\u00e8re M, Khaloun A, Wartelle-Bladou C et al (2012) Future treatment of patients with HCV cirrhosis. Liver Int 32(Suppl 1):113\u2013119","journal-title":"Liver Int"},{"issue":"Suppl N1","key":"3573_CR14","first-page":"1","volume":"58","author":"M Manns","year":"2013","unstructured":"Manns M, Vierling JM, Bacon BR et al (2013) High sustained viral response at 12- and 24-week follow-up of MK-7152 with pegylated interferon alfa-2a and ribavirin in HCV genotype 1 treatment-naive non-cirrhotic patients. J Hepatol 58(Suppl N1):1","journal-title":"J Hepatol"},{"key":"3573_CR15","first-page":"P848","volume-title":"High concordance of SVR4, SVR12, SVR24 in patients with HCV infection who have received treatment with sofosbuvir","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Gane E, Lalezari J et al (2013) High concordance of SVR4, SVR12, SVR24 in patients with HCV infection who have received treatment with sofosbuvir. The International Liver Congress, Amsterdam, p P848"},{"issue":"5","key":"3573_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.20546\/ijcmas.2016.505.029","volume":"5","author":"N Elwan","year":"2016","unstructured":"Elwan N, Elfert A, Abd-Elsalam S et al (2016) Study of hepatic steatosis index in patients with chronic HCV infection. Int J Curr Microbiol App Sci 5(5):266\u2013274","journal-title":"Int J Curr Microbiol App Sci"},{"issue":"5","key":"3573_CR17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","volume":"62","author":"PJ Ruane","year":"2015","unstructured":"Ruane PJ, Ain D, Stryker R et al (2015) Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62(5):1040\u20131046","journal-title":"J Hepatol"},{"key":"3573_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:1993\u20132001","journal-title":"N Engl J Med"},{"key":"3573_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483\u20131493","journal-title":"N Engl J Med"},{"key":"3573_CR20","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/hep.26096","volume":"57","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Poordad F, Manns MP et al (2013) Anemia during treatment with peg interferon alfa-2b\/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 57:974\u2013984","journal-title":"Hepatology"},{"key":"3573_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jhep.2014.05.001","volume":"61","author":"European Association for the Study of the Liver diseases","year":"2014","unstructured":"European Association for the Study of the Liver diseases (2014) EASL recommendations on treatment of hepatitis C. J Hepatol 61:373\u2013395","journal-title":"J Hepatol"},{"key":"3573_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD IDSA recommendations for testing, managing and treating adults infected with hepatitis C virus. Hepatology 62:932\u2013954","journal-title":"Hepatology"},{"issue":"4 suppl","key":"3573_CR23","first-page":"133A","volume":"60","author":"GE Esmat","year":"2014","unstructured":"Esmat GE, Shiha G, Omar RF et al (2014) Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV. Hepatology 60(4 suppl):133A","journal-title":"Hepatology"},{"issue":"3","key":"3573_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","volume":"63","author":"W Doss","year":"2015","unstructured":"Doss W, Shiha G, Hassany M et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581\u2013585","journal-title":"J Hepatol"},{"issue":"5","key":"3573_CR25","doi-asserted-by":"publisher","first-page":"e35339","DOI":"10.5812\/hepatmon.35339","volume":"16","author":"HM Dabbous","year":"2016","unstructured":"Dabbous HM, Montasser IF, Sakr MA et al (2016) Safety, efficacy, and tolerability of sofosbuvir and ribavirin in management of recurrent hepatitis C virus genotype 4 after living donor liver transplant in Egypt: What have we learned so far? Hepat Mon 16(5):e35339","journal-title":"Hepat Mon"},{"issue":"2","key":"3573_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/hep.28611","volume":"64","author":"P Halfon","year":"2016","unstructured":"Halfon P, Mohamed S, Penaranda G et al (2016) Hepatitis C genotype 4R resistance-associated polymorphisms: the achilles heel of the nonstructural 5A inhibitors? Hepatology 64(2):697\u2013698","journal-title":"Hepatology"},{"issue":"6","key":"3573_CR27","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","volume":"149","author":"GR Foster","year":"2015","unstructured":"Foster GR, Pianko S, Brown A et al (2015) Efficacy of\u00a0sofosbuvir\u00a0plus\u00a0ribavirin\u00a0with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with\u00a0cirrhosis\u00a0and hepatitis C virus genotype 2 infection. Gastroenterology 149(6):1462\u20131470","journal-title":"Gastroenterology"},{"issue":"4","key":"3573_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jhep.2015.11.034","volume":"64","author":"MW Welker","year":"2015","unstructured":"Welker MW, Luhne S, Lange CM et al (2016) Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin\/sofosbuvir treatment. J Hepatol 64(4):790\u2013799. doi:10.1016\/j.jhep.2015.11.034","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1007\/s00705-017-3573-0","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"record-id":"39215"},{"DOI":"10.1007\/s00705-022-05600-w","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"record-id":"39214"},{"DOI":"10.1007\/s00705-017-3573-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000}},{"DOI":"10.1007\/s00705-022-05600-w","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000}}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-017-3573-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-017-3573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:18:42Z","timestamp":1772021922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-017-3573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s00705-017-3573-0","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]},"assertion":[{"value":"22 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: The Editor-in-Chief is currently investigating this article as concerns have been raised about the reporting of this clinical trial. Further editorial action will be taken as appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00705-022-05600-w","URL":"https:\/\/doi.org\/10.1007\/s00705-022-05600-w","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of support"}},{"value":"All authors declared that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}